Payment overview · 2025
General Payments
$722.70
37 reported records · 14 companies
Healthcare provider profile · identity verified
Scott Randall Towbin, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PORT ST LUCIE, FL · NPI 1750319521
Verified facts
What the public records show
CMS Open Payments records show Scott Randall Towbin, M.D. received $722.70 in general payments during 2025 across 37 reported records.
PFIZER INC. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $142.08 | 19.7% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $103.09 | 14.3% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $69.80 | 9.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.63 | 8.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.68 | 8.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.42 | 6.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.95 | 6.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.40 | 6.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.29 | 6.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $26.89 | 3.7% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $23.61 | 3.3% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $23.45 | 3.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.15 | 2.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.26 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $722.70 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $136.38 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $125.29 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $69.80 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $61.35 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $59.63 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $58.68 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.42 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.95 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.95 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $44.40 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.74 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $26.89 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.73 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $23.45 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $5.70 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 142 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 262 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 26 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 88 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
88 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
142 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
262 | 58 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 936 | 266 |
| Alprazolam | Alprazolam | 902 | 176 |
| Amlodipine Besylate | Amlodipine Besylate | 860 | 251 |
| Losartan Potassium | Losartan Potassium | 802 | 231 |
| Levothyroxine Sodium | Levothyroxine Sodium | 706 | 199 |
| Lisinopril | Lisinopril | 653 | 194 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 583 | 170 |
| Omeprazole | Omeprazole | 520 | 142 |
| Pravastatin Sodium | Pravastatin Sodium | 502 | 140 |
| Gabapentin | Gabapentin | 475 | 123 |
| Trazodone Hcl | Trazodone Hcl | 429 | 129 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 403 | 72 |
| Metformin Hcl | Metformin Hcl | 399 | 115 |
| Metoprolol Tartrate | Metoprolol Tartrate | 398 | 110 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 357 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 336 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 324 | 99 |
| Oxycodone Hcl | Oxycodone Hcl | 315 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 308 | 100 |
| Zolpidem Tartrate | Zolpidem Tartrate | 300 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 286 | 87 |
| Methylprednisolone | Methylprednisolone | 275 | 194 |
| Hydrochlorothiazide | Hydrochlorothiazide | 273 | 81 |
| Famotidine | Famotidine | 270 | 85 |
| Tramadol Hcl | Tramadol Hcl | 269 | 59 |
| Ozempic | Semaglutide | 262 | 58 |
| Simvastatin | Simvastatin | 242 | 72 |
| Fluticasone Propionate | Fluticasone Propionate | 235 | 90 |
| Atenolol | Atenolol | 209 | 59 |
| Diazepam | Diazepam | 208 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 202 | 57 |
| Clonazepam | Clonazepam | 196 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 196 | 68 |
| Furosemide | Furosemide | 195 | 61 |
| Lorazepam | Lorazepam | 189 | 37 |
| Eliquis | Apixaban | 173 | 53 |
| Sertraline Hcl | Sertraline Hcl | 169 | 49 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 168 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 164 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 160 | 45 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 144 | 16 |
| Mounjaro | Tirzepatide | 142 | 29 |
| Carvedilol | Carvedilol | 137 | 43 |
| Temazepam | Temazepam | 119 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 31 |
| Mirtazapine | Mirtazapine | 109 | 36 |
| Azithromycin | Azithromycin | 107 | 92 |
| Amitriptyline Hcl | Amitriptyline Hcl | 103 | 31 |
| Celecoxib | Celecoxib | 103 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 103 | 25 |
| Montelukast Sodium | Montelukast Sodium | 101 | 34 |
| Pregabalin | Pregabalin | 101 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 29 |
| Meloxicam | Meloxicam | 99 | 25 |
| Potassium Chloride | Potassium Chloride | 97 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 26 |
| Bupropion Xl | Bupropion Hcl | 88 | 23 |
| Glipizide | Glipizide | 88 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 88 | 25 |
| Allopurinol | Allopurinol | 87 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 80 | 60 |
| Finasteride | Finasteride | 80 | 20 |
| Ibuprofen | Ibuprofen | 80 | 26 |
| Lovastatin | Lovastatin | 80 | 21 |
| Metformin Hcl Er | Metformin Hcl | 80 | 25 |
| Valacyclovir | Valacyclovir Hcl | 76 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 18 |
| Terazosin Hcl | Terazosin Hcl | 67 | 19 |
| Xarelto | Rivaroxaban | 67 | 22 |
| Glimepiride | Glimepiride | 66 | 20 |
| Warfarin Sodium | Warfarin Sodium | 66 | 15 |
| Baclofen | Baclofen | 65 | 23 |
| Ezetimibe | Ezetimibe | 64 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 25 |
| Azelastine Hcl | Azelastine Hcl | 63 | 24 |
| Jardiance | Empagliflozin | 63 | 16 |
| Valsartan | Valsartan | 63 | 18 |
| Aripiprazole | Aripiprazole | 60 | 18 |
| Topiramate | Topiramate | 59 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 50 |
| Wegovy | Semaglutide | 57 | 12 |
| Benazepril Hcl | Benazepril Hcl | 56 | 13 |
| Clonidine Hcl | Clonidine Hcl | 56 | 16 |
| Propranolol Hcl | Propranolol Hcl | 55 | 17 |
| Synthroid | Levothyroxine Sodium | 55 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | 12 |
| Spironolactone | Spironolactone | 47 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 16 |
| Fenofibrate | Fenofibrate | 45 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 12 |
| Ketoconazole | Ketoconazole | 42 | 17 |
| Linzess | Linaclotide | 41 | 14 |
| Meclizine Hcl | Meclizine Hcl | 40 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 35 |
| Chlorthalidone | Chlorthalidone | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 31 |
| Methocarbamol | Methocarbamol | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 11 |
| Lidocaine | Lidocaine | 36 | suppressed |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Prednisone | Prednisone | 36 | 19 |
| Carisoprodol | Carisoprodol | 35 | suppressed |
| Estradiol | Estradiol | 35 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Ramipril | Ramipril | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | 11 |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 15 |
| Hydromorphone Hcl | Hydromorphone Hcl | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Epinephrine | Epinephrine | 17 | 14 |
| Folic Acid | Folic Acid | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Tretinoin | Tretinoin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $722.70 · 37 records | PFIZER INC. | AIRSUPRA, CAPVAXIVE, Cologuard Collection Kit, Flector, Licart, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, Tirosint, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error